Ken Griffin, the founder of Citadel Advisors, recently made headlines by selling off over 5.1 million shares of Palantir Technologies, representing over 91% of his holdings in the stock. This decision followed poor timing, as Palantir’s value has surged over 100% since the sale. In contrast, Griffin invested heavily in Biogen, acquiring 372,000 shares, which now shows a significant loss. Analysts suggest potential upside for Biogen, but the company is facing intense market competition and uncertainties in the healthcare sector.
Billionaire investor Ken Griffin dumped over 5.1 million shares of Palantir Technologies, while heavily investing in Biogen, which he currently faces a loss on.
Collection
[
|
...
]